- Home
- MBC vs GERN Comparison
MBC vs GERN Comparison
Compare MBC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- GERN
- Stock Information
- Founded
- MBC 1954
- GERN 1990
- Country
- MBC United States
- GERN United States
- Employees
- MBC N/A
- GERN N/A
- Industry
- MBC Agricultural Chemicals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- GERN Health Care
- Exchange
- MBC Nasdaq
- GERN Nasdaq
- Market Cap
- MBC 1.8B
- GERN 1.5B
- IPO Year
- MBC N/A
- GERN 1996
- Fundamental
- Price
- MBC $13.78
- GERN $1.73
- Analyst Decision
- MBC Strong Buy
- GERN Strong Buy
- Analyst Count
- MBC 1
- GERN 12
- Target Price
- MBC $19.00
- GERN $5.73
- AVG Volume (30 Days)
- MBC 1.3M
- GERN 20.3M
- Earning Date
- MBC 02-18-2025
- GERN 05-01-2025
- Dividend Yield
- MBC N/A
- GERN N/A
- EPS Growth
- MBC N/A
- GERN N/A
- EPS
- MBC 0.96
- GERN N/A
- Revenue
- MBC $2,700,400,000.00
- GERN $76,994,000.00
- Revenue This Year
- MBC $11.21
- GERN $283.80
- Revenue Next Year
- MBC N/A
- GERN $83.15
- P/E Ratio
- MBC $14.35
- GERN N/A
- Revenue Growth
- MBC N/A
- GERN 32386.92
- 52 Week Low
- MBC $12.68
- GERN $1.46
- 52 Week High
- MBC $20.67
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- MBC 35.13
- GERN 24.57
- Support Level
- MBC $12.68
- GERN $1.62
- Resistance Level
- MBC $15.06
- GERN $1.91
- Average True Range (ATR)
- MBC 0.75
- GERN 0.15
- MACD
- MBC -0.13
- GERN -0.04
- Stochastic Oscillator
- MBC 26.32
- GERN 21.77
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.